Ratings CONMED Corporation

Equities

CNMD

US2074101013

Real-time Estimate Cboe BZX Other stock markets 18:11:23 29/04/2024 BST			5-day change	1st Jan Change
66.24 ^USD	+0.70%		-8.92%	-39.61%

04-25	Wells Fargo Adjusts Price Target on CONMED to $77 From $98, Maintains Equalweight Rating	MT
04-25	Needham Lowers Price Target on CONMED to $107 From $129, Notes Slight Guidance Cut Due to Currency, Keeps Buy Rating	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
CONMED CORPORATION	-39.61%	2.03B	B-
ABBOTT LABORATORIES	-2.69%	187B	C+
MEDTRONIC PLC	-1.59%	106B	C
BECTON, DICKINSON AND COMPANY	-4.33%	66.9B	A
DEXCOM, INC.	+0.58%	49.45B	B-
CENCORA, INC.	+16.93%	48B	B-
HOYA CORPORATION	+4.06%	40.84B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+3.71%	26.48B	B
WEST PHARMACEUTICAL SERVICES, INC.	+1.27%	26.25B	A-
TERUMO CORPORATION	+12.96%	24.62B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes